Because impaired VLDL export with reduced MTP could be a primary disorder of FLS mice,[8] we focused on hepatic MTP in this model. Although there were no differences in the

mRNA level of MTP and MTP activity between EZ and CT, the protein level of MTP in EZ was significantly higher than that in CT. Thus, the increased MTP protein level without an increased mRNA level could be due to reduced post-translational degradation.[19] selleckchem A previous study showed that CCL4 induced degradation of MTP protein without affecting its lipid transfer activity, and MTP antagonists inhibited lipid transfer activity without causing its degradation.[19] Hence, we highlighted a novel post-transcriptional mechanism for controlling MTP function via ubiquitination of MTP. Post-translational control of protein degradation by the ubiquitin proteasome system (UPS) is highly regulated through intracellular protein degradation in a specific manner. Modification of proteins via covalent attachment of ubiquitin is a three-step cascade involving ubiquitin-activating (E1), ubiquitin-conjugating (E2) and ubiquitin-ligating (E3) enzymes,[25] and the two major E3 complexes of UPS involved in protein degradation are SCFSkp2 and APCCdc20 DAPT cost complexes.[26, 27] In the present study, the protein

expression of Skp2 and CDC20 in the liver of FLS was reduced by administration of ezetimibe, suggesting that ezetimibe prevented ubiquitination and degradation of MTP protein via suppression of its ubiquitin ligation. Therefore, the effect of ezetimibe of preventing NAFLD, if any, could be via suppression of degradation of hepatic MTP protein. In order to clarify whether ezetimibe has a direct or an indirect effect on degradation

of hepatic O-methylated flavonoid MTP protein, we investigated the effects of ezetimibe in rat hepatoma cells with or without CCL4 treatment. A previous study showed that CCL4 treatment enhanced ubiquitination and degradation of MTP in MCA-RH7777 cells.[19] Our study demonstrated that although the protein levels of Skp2 and CDC20 were decreased, ezetimibe-treated cells did not show enhanced protein expression of MTP or decreased ubiquitination of MTP compared with DMSO-treated cells. Thus, this finding suggests that ezetimibe may have had an indirect effect on the liver by preventing ubiquitination and degradation of MTP protein. In the present study, CCL4 treatment induced hepatic ROS, consistent with a previous report,[28] and ezetimibe administration significantly reduced the hepatic ROS level. A previous study in rats revealed that ROS generation and endoplasmic reticulum (ER) stress were reduced by treatment with ezetimibe.[29] Because ER stress and ROS are considered to play a role in the development of NASH from simple fatty liver, it is speculated that ezetimibe-induced prevention of NAFLD was partially via its effect of decreasing cellular ROS.